They are now dealing with the vaccine in each manner, however they would have ultimately resulted (in developing their own variation of the) COVID-19 vaccine, and we will be facilitating the production.
Jakarta – Minister of Research Study and Innovation Bambang PS Brodjonegoro has stated 6 research entities are currently developing Indonesia’s native vaccine against COVID-19, Merah Putih, hence, numerous variations of the vaccine would eventually be released.
” Considering that they (the research teams) are using different platforms, the result would also be some 6 versions of the vaccine,” Brodjonegoro said throughout an online interview held at the National Company of Disaster Management (BNPB) structure in Jakarta on Tuesday.
” They are now dealing with the vaccine in each manner, but they would have eventually resulted (in developing their own version of the) COVID-19 vaccine, and we will be helping with the production,” he included.
The six entities dealing with the vaccine are the Eijkman Institute for Molecular Biology, the Indonesian Institute of Sciences (LIPI), Gadjah Mada University, University of Indonesia, Airlangga University, and Bandung Institute of Technology.
The Eijkman is presently leading vaccine advancement. Work on its vaccine, which is based upon a recombinant sub-unit protein platform, has actually progressed more than 50 per cent on the lab scale, and the vaccine is anticipated to enter the stage of pre-clinical screening on animals by November, 2020.
LIPI, on the other hand, is using recombinant combination proteins as its vaccine platform, while Gadjah Mada University is developing a recombinant protein platform.
University of Indonesia is utilizing DNA, mRNA, and virus-like particles for its COVID-19 vaccine.
Bandung Institute of Innovation is dealing with an adenoviral platform, while Airlangga University is utilizing both adenoviral and adeno-associated viral (AAV) platforms to develop its vaccine.
Brodjonegoro has charged the research study institutions as well as his ministry with developing the vaccine model. The vaccine’s further development, including clinical trials and production, will be undertaken by state-owned drug store company Bio Farma.
Bio Farma, the minister stated, plans to establish a consortium with Indonesian private-run business to produce the Merah Putih vaccine at a greater capability in the future.
Related news: Merah Putih vaccine’s preclinical trial phase forecasted by year-end
Associated news: Bio Farma projected COVID-19 vaccine “Merah Putih” roll-out by 2022